Agomab Therapeutics NV ('Agomab') today announced that Tim Knotnerus, Chief Executive Officer, will present a company overview and update at the virtual 40th Annual J.P. Morgan Healthcare Conference
Agomab Therapeutics NV ('Agomab') today announced the expansion of its team with two key hires: Reginald Brys will join as Head of Research and Maria Nichol will become Head of Intellectual Property.
Financing round co-led by 5AM Ventures, Roche Venture Fund and Sofinnova Partners with participation from LimmaTech Biologics AG GlycoEra AG announced today the close of a CHF 45 million ($49 million)
Acquisition strengthens Agomab as a leader in targeting growth factor pathways Origo brings TGF-ß-targeted approach with clinical-stage program in Crohn's disease and preclinical candidate